止血產品市場規模、佔有率及成長分析（按產品、應用、最終用途及地區）－2025 年至 2032 年產業預測

預計止血產品市場規模將在 2023 年達到 16.9 億美元，並從 2024 年的 17.8 億美元成長到 2032 年的 27.4 億美元，預測期內（2025-2032 年）的複合年成長率為 5.5%。

在醫療意識不斷提高和醫療技術不斷進步的推動下，全球止血產品市場正在持續成長。這些產品對於控制手術和創傷期間的出血以及治療出血性疾病至關重要，由於人口老化以及慢性疾病和外科手術的增加，對這些產品的需求正在成長。此外，新興市場醫療保健基礎設施的改善也進一步推動了市場擴張。持續的研究和開發正在帶來創新、更安全、更有效率的產品。然而，這些產品的監管障礙和高成本對市場成長構成了挑戰。儘管存在這些障礙，但隨著醫療保健標準和技術創新的發展，市場仍有望繼續發展。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

止血產品市場規模：依產品及複合年成長率（2025-2032）

• 市場概覽
• 局部止血
  • 膠原蛋白
  • 氧化再生纖維素
  • 明膠
  • 多醣
• 點滴止血
  • 捐捐血液中的濃縮血小板
  • 血液來源的 FVIII
  • 新鮮冰凍血漿
  • 凝血酶原複合物
• 高級止血
  • 液體止血劑
  • 凝血酶
  • 纖維蛋白
  • 合成密封膠

止血產品市場規模：依應用與複合年成長率（2025-2032）

• 市場概覽
• 創傷
• 外科手術
• 血友病
• 心肌梗塞
• 中風
• 血栓症

止血產品市場規模：依最終用途及複合年成長率（2025-2032）

• 市場概覽
• 醫院
• 門診手術中心
• 其他

止血產品市場規模：依地區及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• CSL Behring（Australia）
• Haemonetics Corporation（USA）
• Octapharma AG（Switzerland）
• Baxter International Inc.（USA）
• Johnson & Johnson（USA）
• Pfizer Inc.（USA）
• Becton, Dickinson and Company（USA）
• Medtronic plc（Ireland）
• Siemens Healthineers AG（Germany）
• Abbott Laboratories（USA）
• Roche Holding AG（Switzerland）
• Thermo Fisher Scientific Inc.（USA）
• Grifols, SA（Spain）
• Instrumentation Laboratory（Werfen）（USA）
• Stago Group（France）
• Sysmex Corporation（Japan）
• Siemens Healthineers AG（Germany）
• Danaher Corporation（USA）
• LivaNova PLC（UK）
• CryoLife, Inc.（USA）

結論和建議

Hemostasis Products Market size was valued at USD 1.69 billion in 2023 and is poised to grow from USD 1.78 billion in 2024 to USD 2.74 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

The global hemostasis products market is experiencing consistent growth, fueled by heightened awareness and medical technology advancements. Essential for controlling bleeding during surgeries, trauma, and managing bleeding disorders, the demand for these products is amplified by an aging population and an increase in chronic diseases and surgical procedures. Additionally, improvements in healthcare infrastructure in developing regions are further propelling market expansion. Ongoing research and development are introducing innovative, safer, and more efficient hemostasis products. Nevertheless, regulatory hurdles and the high costs associated with these products present challenges to market growth. Despite these obstacles, the market is set for continued progress as healthcare standards and technological innovations evolve.

Top-down and bottom-up approaches were used to estimate and validate the size of the Hemostasis Products market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Hemostasis Products Market Segments Analysis

Global Hemostasis Products Market is segmented by Products, Application, End Use and region. Based on Products, the market is segmented into Topical Hemostasis, Infusible Hemostasis and Advanced Hemostasis. Based on Application, the market is segmented into Trauma, Surgery, Hemophilia, Myocardial Infarction, Stroke and Thrombosis. Based on End Use, the market is segmented into Hospitals, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Hemostasis Products Market

The Hemostasis Products market is significantly driven by innovations that focus on the development of safer and more environmentally friendly hemostatic solutions, including advanced agents and devices. These advancements not only enhance the management of bleeding complications and surgical processes but also contribute to better patient outcomes. As these improved products gain traction, they are stimulating growth within the market, leading to increased demand for effective hemostatic solutions. The ongoing emphasis on safety and effectiveness in hemostasis products plays a crucial role in shaping the future of medical practices related to bleeding control and surgical interventions.

Restraints in the Hemostasis Products Market

A significant challenge in the hemostasis products market is the high cost of these items. The elevated prices can limit accessibility for healthcare facilities with constrained budgets, as well as for patients in various regions. This financial barrier may impede the widespread adoption of advanced hemostasis solutions, ultimately restricting their market penetration. As a result, the impact on patient care could be substantial, as many healthcare providers may struggle to incorporate these critical products into their treatment protocols due to budgetary constraints, leading to disparities in the quality of care available to patients.

Market Trends of the Hemostasis Products Market

The Hemostasis Products market is witnessing a notable trend toward minimally invasive techniques, driven by a collective demand from healthcare providers and patients for less invasive solutions to manage bleeding during surgical procedures. This shift is propelling the development of advanced hemostasis products that minimize tissue damage, streamline recovery times, and enhance overall patient outcomes. As these techniques gain popularity, they offer increased patient comfort and shorter hospital stays, aligning perfectly with the healthcare industry's broader focus on value-based care. Consequently, manufacturers are innovating rapidly to meet these evolving needs, making the market poised for substantial growth.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hemostasis Products Market Size by Products & CAGR (2025-2032)

• Market Overview
• Topical Hemostasis
  • Collagen
  • Oxidized Regenerated Cellulose
  • Gelatin
  • Polysaccharide
• Infusible Hemostasis
  • Platelet Concentrates from Donor Blood
  • FVIII Derived from Blood
  • Fresh Frozen Plasma
  • Prothrombin Complex
• Advanced Hemostasis
  • Flowable
  • Thrombin
  • Fibrin
  • Synthetic Sealants

Global Hemostasis Products Market Size by Application & CAGR (2025-2032)

• Market Overview
• Trauma
• Surgery
• Hemophilia
• Myocardial Infarction
• Stroke
• Thrombosis

Global Hemostasis Products Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Others

Global Hemostasis Products Market Size & CAGR (2025-2032)

• North America (Products, Application, End Use)
  • US
  • Canada
• Europe (Products, Application, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Products, Application, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Products, Application, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Products, Application, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haemonetics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Instrumentation Laboratory (Werfen) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stago Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LivaNova PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CryoLife, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations